- Dec 20, 2017

Immunotherapy drug nearly eliminates severe acute graft-versus-host disease

Results from a phase 2 clinical trial, presented by Seattle Children's Research Institute at the 59th American Society of Hematology (ASH) Annual Meeting, show that the drug Abatacept (Orencia) nearly eliminated life-threatening severe acute graft-versus-host disease (GvHD) in patients receiving hematopoietic stem cell transplants.

Cancer researchers team up against deadliest brain tumors in children

Nanomedicine research into drug delivery system a 'milestone' in the treatment of childhood cancer

New study identifies bereaved parents’ medical priorities for children with advanced cancer

Anesthesia for pediatric cancer patients: What parents should know

Childhood Cancer Survivors Have Increased Rates of Late, Major Surgeries

Advanced immunotherapy treatment may hold promise for children with brain cancer

Organoid models provide new scientific insights into a rare childhood liver cancer

Caring for adult children with cancer: 4 tips for parents

Study explores psychosocial needs of African American parents of children with cancer

Immunotherapy improves the prognosis of babies with a very aggressive leukemia

Recent Posts

Immunotherapy drug nearly eliminates severe acute graft-versus-host disease

Archive